Latest News and Press Releases

BASEL, Switzerland, April 16, 2026 (GLOBE NEWSWIRE) -- BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated...

BASEL, Switzerland, April 15, 2026 (GLOBE NEWSWIRE) -- Poster presentations to feature data from clinical asset BV100 addressing carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex...

BASEL, Switzerland, April 13, 2026 (GLOBE NEWSWIRE) -- BioVersys and partners publish in the prestigious journal of Nature Communications pre-clinical development data of AlpE (alpibectir and...

BASEL, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- BioVersys strengthens its Ansamycin Chemistry platform and research on tackling difficult-to-treat non-tuberculous mycobacteria (NTM)...

BASEL, Switzerland, March 18, 2026 (GLOBE NEWSWIRE) -- Significant clinical and regulatory progress across entire pipeline BV100: Initiated global registrational Phase 3 (RIV-TARGET) in...

Ad hoc announcement pursuant to Art. 53 LR BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial...

Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, March 12, 2026 (GLOBE NEWSWIRE) -- Under the BioVersys and GSK collaboration agreement, AlpE clinical development...

BASEL, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial...

BASEL, Switzerland, March 04, 2026 (GLOBE NEWSWIRE) -- BV100 Phase 1, single- and multiple-ascending dose clinical trial data include pharmacokinetics, safety and tolerability data. BV100...

Data from Phase 2a study demonstrated the first clinical proof of concept for alpibectir in combination with ethionamide (AlpE) in the treatment of patients with tuberculosis. The results, published...